Nuvalent (NUVL) Other Operating Expenses (2024 - 2025)
Nuvalent (NUVL) reported Other Operating Expenses of $285.8 million for Q4 2025, up 208.73% on a YoY basis from $92.6 million in Q4 2024, and up 382.3% quarter-over-quarter from -$101.2 million in Q3 2025.
Nuvalent (NUVL) Other Operating Expenses (2024 - 2025) Analysis & Trends
Nuvalent has reported Other Operating Expenses for 2 years, with the latest figure at $285.8 million in Q4 2025.
- For the quarter ending Q4 2025, Other Operating Expenses rose 208.73% year-over-year to $285.8 million; the trailing twelve-month figure through Mar 2026 stood at $87.8 million (up 133.41% YoY), and the FY2024 full-year result was -$262.9 million, changed N/A from the prior year.
- Other Operating Expenses for Q4 2025 stood at $285.8 million, up from -$101.2 million in the prior quarter.
- The five-year high for Other Operating Expenses was $285.8 million in Q4 2025, with the low at -$262.9 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Nuvalent | 9.70 Bn | 9.70 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 285.79 Mn |
| Sep 30, 2025 | -101.24 Mn |
| Jun 30, 2025 | -96.75 Mn |
| Dec 31, 2024 | -262.86 Mn |
| Mar 31, 2024 | -49.52 Mn |